






The Clinical Trial of FK 506 as Primary and Rescue 
Immunosuppression in Pediatric Cardiac Transplantation 
J.M. Armitage, F.J. Fricker, P. Del Nido, L. Cipriani, and T.E. Starzl 
I N CONCERT with the adult trial of FK 506 begun in October 1989 at Presbyterian University Hospital, a 
similar trial to investigate the use of FK 506 as both 
primary and rescue immunotherapy was initiated in the 
pediatric population at Children's Hospital of Pittsburgh. 
In a prospective clinical trial 19 pediatric patients have 
undergone orthotopic cardiac transplantation with FK 506 
and low-dose steroids as primary immunosuppression. 
Encouraging results have also been obtained in four chil-
dren with refractory cardiac rejection who have undergone 
rescue therapy with FK 506. 
PATIENTS AND METHODS 
Patient Group 
Nineteen patients were prospectively entered into this study from 
October 1989 to August 1991. Informed consent was obtained 
from each patient and family before transplantation for the use of 
FK 506 and steroids as the sole immunosuppressive therapy; two 
patients received conventional cyclosporine-based immunosup-
pression during this period. 
In the study group were 14 males and 5 females (age range 5 
days to 17 years). Four patients (21%) required mechanical 
circulatory support before transplantation in the form of Extra 
Corporeal Membrane Oxygenation (ECMO) (3) and Novacor Left 
Ventricular Assist Device (LVAD) (I). Nine (47%) other patients 
awaited transplantation with either ventilatory and/or inotropic 
support. Thus 13 (68%) of 19 patients were UNOS Status I at the 
time of transplantation. The etiology of cardiomyopathy included 
congenital heart disease (ll), idiopathic (6), restrictive (I), and 
viral (1). Median follow-up of these 19 patients was 304 days 
(range 5 to 668 days) as of August 1991. No attempt was made to 
enroll patients selectively in this study based on severity of illness 
or preoperative status. 
The II children with congenital heart disease in many ways 
represented the most challenging problems resulting from mUltiple 
prior operations and their anatomic constraints. The following is a 
list of the congenital disorders for which our pediatric group 
underwent transplantation and their respective ages: hypoplastic 
left heart syndrome (3) (5, 25, and 42 days); transposition of the 
great vessels (2) (2 and 17 years); single ventricle (2) (7 and 14 
years); tricuspid atresia (2) (12 and 17 years); double inlet left 
ventricle and left AV valve atresia (I) (4 years), and cardiomyop-
athy following coarctation of the aorta and left ventricular outflow 
tract obstruction (I) (5 years). 
Four pediatric patients who had cardiac rejection refractory to 
conventional immunosuppressive treatment were treated with FK 
506 rescue therapy. Three of these patients were from our own 
institution and one was referred from an outside center. 
FK 506 Therapy 
FK 506 was administered intravenously for 24 to 72 hours after 
cardiac transplantation at a dose of O.075/mglkg per day in two 
divided doses. Oral FK 506 was begun 24 hours after trans plan-
tation. The oral maintenance dose of FK 506 required to attain a 
level of 0.5 to 1.0 nglmL (12 hour through serum ELISA by the 
technique of Temura) I has ranged from 0.2 to 0.4 mglkg per day. 
Methylprednisolone, 7 mglkg, was administered intravenously in 
the operating room and 5 mglkg postoperatively for 24 hours in 
three divided doses. Thereafter, patients received 0.15 mglkg per 
day prednisone orally once a day. Prednisone was then tapered 
and discontinued based on rejection history. All but three children 
have been tapered off all steroids within the first month posttrans-
plant. 
Other Agents 
All patients entered into the FK 506 immunotherapy protocol 
were placed on prophylactic oral trimethoprimlsulfamethoxazole. 
acyclovir. and Mycostatin. 
Monitoring for Rejection 
Posttransplant surveillance on all patients involved weekly trans-
venous endomyocardial biopsies during hospitalization and at 
slowly increased intervals after discharge. The neonates were 
biopsied at I- to 3-month intervals. Biopsies were graded using 
hematoxylin and eosin staining after light microscopy by a pathol-
ogist who was blinded to the immunosuppressive protocol of the 
patient. Biopsy grades were defined according to standardized 
nomenclature. Rejection was defined by the presence of myocyte 
necrosis in association with an interstitial lymphocytic infiltrate 
(grade 3 or moderate rejection) or with hemorrhage (grade 4 or 
severe rejection). 
Monitoring for Infection 
All patients were followed by an infectious-disease specialist. 
Pretransplant titers for hepatitis B. herpes virus, Epstein-Barr 
virus (EBV), human immunodeficiency virus (HIV), Toxoplasma. 
and cytomegalovirus (CMV) were performed on all donors and 
recipients. The diagnosis of infection was made using clinical 
criteria as previously defined by this institution.2 Complete blood 
screening was performed daily in the hospital and at all follow-up 
visits. Questionnaires to identify untoward side effects of FK 506 
were completed on all patients. 
RESULTS 
Survival 
Seventeen of 19 (89%) patients entered into this trial are 
alive. There were no perioperative (30 days) deaths. There 
From the Dept. of Surgery (T.E.S.), University of Pittsburgh 
School of Medicine, and Children's Hospital of Pittsburgh (J.MA, 
F.J.F., P.D.N., L.C.), Pittsburgh, Pennsylvania. 
Address reprint requests to John M. Armitage, MD, Dept. of 
Surgery, 1084 Scaife Hall, University of Pittsburgh, Pittsburgh, PA 
15261. 
© 1991 by Appleton & Lange 
0041-1345/91/$3.00/+0 
3058 Transplantation Proceedings, Vol 23, No 6 (December), 1991: pp 3058-3060 
.' 
r $: .. i,": ... ":-.'.. FK 506 IN PEDIATRIC CARDIAC TRANSPLANT were two late deaths, one (90 days) secondary to sepsis in 
a child with preexisting lung disease and bronchiectasis 
-t;: who succumbed to pulmonary and disseminated crypto-
coccal infection. This child also suffered from severe 
cardiac cachexia with associated ascites, hypoalbumin-
aemia, and hypogammaglobulinaemia. His immunosup-
pression consisted of very low dose FK 506 without 
steroids. and no cardiac rejection occurred. The second 
death (120 days) was secondary to posttransplant lympho-
proliferative disease (PTLD) and an associated dissemi-
nated CMV infection in a 6-year-old girl on FK 506 as her 
sole immunosuppressive agent. No mortality has been 
directly attributed to FK 506 therapy or to acute or 
refractory rejection. 
Rejection 
At 3 months posttransplant there were 14 episodes of 
rejection (grade 3A or greater) in 19 patients, or 0.7 
episodes per patient. Seven of these 14 episodes of rejec-
tion occurred in two patients, one of whom had a panel 
reactive antibody (PRA) of 55% and one other patient in 
whom FK 506 was administered at a very low dose due to 
a pretransplant creatinine clearance of 20 mL. The actu-
arial freedom from grade 3A rejection was 60% at 3, 6, and 
9 months. 
Rejection episodes of moderate severity (Billingham 
criteria 3A) were preferentially treated by increased doses 
of FK 506, 2 to 4 mg/d. Moderate or severe rejection 
(Billingham criteria 3B or 4) was treated either by intrave-
nous methylprednisolone, 7 mg/kg for 24 or 48 hours, or 
with a short-course oral prednisone taper, 50 mg to to mg 
over 5 days, in those patients whose FK 506 levels were 
already in the high therapeutic range or in whom azotemia 
(BUN >50 and creatinine >2.0) limited further manipula-
tion of FK 506 therapy. 
The two patients mentioned previously in whom seven 
of the episodes of rejection occurred are the only two 
pediatric patients who have required the addition of aza-
thioprine as additional immunosuppressive therapy. The 
young boy with the preexisting renal dysfunction was also 
treated with one course of OKT3. 
Infection 
There were seven major infections in 4 of 19 patients 
(21%). One neonate with HLHS and a prolonged ICU 
course developed line sepsis (staphylococcal), peritonitis 
from a peritioneal dialysis catheter, and an episode of 
parainfluenza pneumonia; he has recovered well and is 
now over 1 year of age. A second neonate transplanted for 
HLHS had an uneventful perioperative course but re-
turned 4 weeks later with candida sepsis secondary to 
pyelonephritis and has recovered following amphotericin 
therapy. Two deaths occurred with associated sepsis (see 
section on Survival above). One other child recovered 
from a CMV pneumonia following gancyclovir therapy. 
There have been six minor infections in 5 (26%) of 19 
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patients. There were two varicella infections and three 
patients with sinusitis (two of which were sterile). A 
critically ill child following prolonged CPR and ECMO 
support developed CMV in the urine, which resolved with 
appropriate treatment. 
Cardiac Function 
All surviving patients enjoy excellent cardiac function. 
The average left ventricular ejection fraction (LVEF) in 
the group measured by gated nuclear scan and/or echocar-
diography was 66%. The range of LVEF was 60% to 75% 
at the time of longest follow-up. 
Renal Function and Hypertension 
FK 506 was extremely well tolerated in the pediatric group 
of cardiac transplant recipients. The average pretransplant 
serum creatinine was 0.7 ng/dL (std. err. 0.1) and at 3 
months posttransplant was 0.9 ng/dL (std. err. 0.1). Mod-
erate oliguria and transient azotemia was associated with 
the IV administration of FK 506 particularly if preexisting 
renal dysfunction was present. Two patients required 
temporary peritoneal dialysis; one patient had renal vein 
thrombosis secondary to IV lines and the other was in 
anuric renal failure pretransplant secondary to cardiac 
arrest. Normal renal function has returned in both of these 
patients. 
Only two patients have required antihypertensive ther-
apy. One patient remains on antihypertensive treatment 
and she was hypertensive prior to transplant. The other 
patient's blood pressure has normalized following repair of 
an aortic coarctation. Compared to the prior cycIosporine 
(CyA) era in which the incidence of hypertension was 
70%, this represents a dramatic reduction in the necessity 
to treat hypertension posttransplant (P < .ool). 
Cardiac Rescue Therapy 
Four patients who suffered from cardiac rejection refrac-
tory to aggressive conventional immunotherapy were 
treated with FK 506. All of these patients had been treated 
with CyA, azathioprine. and steroids; all had received two 
or more courses of intravenous steroids and one or more 
courses of antilymphocyte therapy (RATG, Minnesota 
ALG, or OKT3) and had persistent rejection. 
The rescue patients tolerated the switch from Cy A to 
FK 506 without significant complications. Cyclosporine 
was discontinued 24 to 48 hours prior to FK 506 induction. 
No loading dose of FK 506 was administered. The patients 
were begun on oral FK 506, 0.3 mglkg per day, in two 
divided doses. Azathioprine was discontinued and steroids 
were given at half the maintenance dose. Pending improve-
ment in subsequent biopsies, steroids were tapered and all 
eight patients are on one-quarter their previous prednisone 
dose. All patients have either resolved or significantly 
improved the histologic endomyocardial biopsy grading of 
rejection. One rescue patient died of suicide. 
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Metabolic Studies and Side Effects 
No pediatric patient on primary or rescue FK 506 immu-
notherapy has required insulin therapy or had abnormal 
fasting blood sugars. Continued monitoring of hematologic 
and coagulation indices, as well as hepatic function, failed 
to reveal any abnormalities in our patients at this follow-up 
interval. Cholesterol and triglycerides have been slightly 
lower than those in CyA-treated patients; however, this 
was not statistically significant. Four patients had border-
line elevated uric acid levels. Slightly elevated serum 
potassium levels have also been observed in some pa-
tients, independent of renal dysfunction, and we have 
avoided the exogenous administration of potassium in this 
group unless specifically indicated (serum K+ <3.5 mEq/ 
L). Anemia (hematocrit <28) has been problematic in 
almost 30% of the children on FK 506. One of these 
children had an associated parvovirus infection to which 
the anemia could be attributed. The other five children 
have had completely normal anemia studies including bone 
marrow biopsies. This anemia is associated with low 
erythropoietin and reticulocyte levels and has responded 
well to erythropoietin therapy. Further evaluation of the 
mechanism of this anemia is under study. 
Side effects have been rare despite routine question-
naires during hospitalization and during outpatient follow-
up. There have been no seizures, cerebrovascular acci-
dents (CVA), or neuropathies secondary to FK 506. One 
patient in the primary therapy group had an intracerebral 
hemorrhage and seizure from which she recovered with 
little residual deficit. There have been occasional reports 
of extremity paresthesia and temperature malsensations 
usually associated with elevated FK 506 levels. Muscle 
aches and mild insomnia were also reported rarely. Nota-
bly absent in this patient group were complaints of gingiVal 
hyperplasia, tremor, or hirsutism. 
DISCUSSION 
The results from this prospective trial of FK 506 as 
immunotherapy in pediatric patients following cardiac 
transplantation have been dramatic. The pediatric popula-
tion, previously the more problematic group in terms of 
rejection and hypertension when compared to the adult 
group during the Cy A era, has become relatively easy to 
manage. As a way of illustrating the dramatic improve-
ment realized in this pediatric cardiac transplant group, the 
actuarial freedom from grade 3A rejection at 3 and 6 
months posttransplant on FK 506 was 60% vs 20% and 
12%, respectively, for the 15 children transplanted prior to 
the use of FK 506 on Cy Aiazathioprine/steroids (P < .00 I). 
Equally impressive, but not apparent in these statistics, is 
ARMITAGE, FRICKER, DEL NIDO ET AL 
that only 20% of the children in the FK 506 group were on 
steroids at these follow-up intervals vs 100% of the Cy A 
group who remained on high-dose steroids. This level of 
immunosuppression has been attained without antilyrr 
phocyte therapy. without immunoprophylaxis, withol. 
azathioprine. and with marked reduction in steroid re-
quirement. As further evidence of the potency and selec-
tivity of the immunosuppressant effects of FK 506 it has 
been more difficult to propagate lymphocytes from endo-
myocardial biopsies from patients treated with FK 506 
than those previously treated with Cy A triple-drug ther-
apy, particularly at higher histologic grades. Another 
added advantage of FK 506 is the flexibility it introduces to 
i?lmunosuppressive management. Mild to moderate rejec-
~lon th~t occurred. was preferentially treated merely by 
mcreasl~g t~e restmg level of FK 506. The concept of 
~ug?lentm~ fmm~nosuppression and thereby treating re-
Jection by mcreasmg baseline immunotherapy introduces a 
new tool to our armamentarium of antirejection therapy. 
Side effects and toxicity have been few. Renal dysfunc 
tion has been minimal. Hirsutism. gingivitis, and facial 
bone growth abnormalities associated with Cy A have not 
been observed. Annual catheterizations performed to date 
have failed to reveal any coronary abnormalities. The 
marked diminishment in steroid requirement will undoubt-
edly hold promise for improved growth potential and 
diminished obesity, hyperlipidemia. hypertension, and 
cushingoid habitus. 
We are continuing to learn about appropriate FK 506 
dosing and levels. Clearly, this is a potent immunosuppres-
sive agent, and during our early experience moderate 
overdosing occurred. We feel the initial IV loading dose is 
important to initiate the highly specific effects of this agent 
and to prevent up-regulation of the immune system. How-
ever, the initial dose should be limited to 0.075 mg/kg per 
day as a continuous infusion for 24 hours and then discon-
tinued. In children, lower levels of FK 506 produce com-
parable or superior results to that seen in adults. Levels of 
0.4 to 1.0 ng/mL are therapeutic in children. 
Cardiac function and the quality of these children's lives 
have been excellent. We are extremely encouraged by the 
dramatic immune advantage this agent seems to hold for 
the young patient facing cardiac transplantation and a 
future wedded to immunosuppression. We are hopeful that 
the tremendous advantage observed in this preliminary 
study is borne out by more long-term follow-up. 
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